Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Daratumumab

Infusion-related reaction

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Aykas F, et al. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction. Journal of Oncology Pharmacy Practice 30 : 397-399, No. 2, Mar 2024. Available from: URL: https://dx.doi.org/10.1177/10781552231213999 [Summarised from an English abstract] Aykas F, et al. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction. Journal of Oncology Pharmacy Practice 30 : 397-399, No. 2, Mar 2024. Available from: URL: https://​dx.​doi.​org/​10.​1177/​1078155223121399​9 [Summarised from an English abstract]
Metadaten
Titel
Daratumumab
Infusion-related reaction
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56139-3

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Capecitabine

Case report

Denosumab

Case report

Pembrolizumab

Case report

Antineoplastics